Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 6/20 | 0.46 |
| ▸ | FGFR2 | P21802 | 6/20 | 0.46 |
| ▸ | FGFR3 | P22607 | 6/20 | 0.46 |
| ▸ | KDR | P35968 | 5/20 | 0.46 |
| ▸ | KIT | P10721 | 2/20 | 0.43 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.43 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.43 |
| ▸ | AXL | P30530 | 1/20 | 0.43 |
| ▸ | PRKCI | P41743 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 3/20 | 0.36 |
| ▸ | JAK2 | O60674 | 5/20 | 0.36 |
| ▸ | JAK1 | P23458 | 5/20 | 0.36 |
| ▸ | TYK2 | P29597 | 5/20 | 0.36 |
| ▸ | JAK3 | P52333 | 5/20 | 0.36 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.35 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20943869 | 1.00 | FGFR1 (0.46) | FGFR1FGFR2FGFR3KDRKIT | |
| SCHEMBL15555902 | 0.85 | FGFR1 (0.42) | FGFR1FGFR2FGFR3KDRKIT | |
| SCHEMBL15555901 | 0.85 | FGFR1 (0.42) | FGFR1FGFR2FGFR3KDRKIT | |
| SCHEMBL29940336 | 0.77 | MAPT (0.34) | — | |
| SCHEMBL29940738 | 0.77 | MAPT (0.34) | — | |
| SCHEMBL20569821 | 0.77 | MAPT (0.34) | — | |
| SCHEMBL1079890 | 0.73 | AXL (0.62) | FGFR1FGFR2FGFR3KDRKIT | |
| SCHEMBL30731298 | 0.73 | AXL (0.62) | FGFR1FGFR2FGFR3KDRKIT | |
| SCHEMBL15557342 | 0.73 | FGFR1 (0.46) | FGFR1FGFR2FGFR3KDRKIT | |
| SCHEMBL15154891 | 0.70 | KDR (0.47) | FGFR1FGFR2FGFR3KDRKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11840534-B2 | Substituted tricyclic compounds as FGFR inhibitors | INCYTE CORPORATION (US) | 2023-12-12 | — | — | US | disclosed |
| US-11840534-B2 | Substituted tricyclic compounds as FGFR inhibitors | INCYTE CORPORATION (US) | 2023-12-12 | — | — | US | disclosed |
| US-20210380587-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS | INCYTE HOLDINGS CORPORATION | 2021-12-09 | — | — | US | disclosed |
| US-11053246-B2 | Substituted tricyclic compounds as FGFR inhibitors | INCYTE CORPORATION (US) | 2021-07-06 | — | — | US | disclosed |
| US-20200377504-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS | INCYTE CORPORATION | 2020-12-03 | — | — | US | disclosed |
| CN-107652289-B | Substituted tricyclic compounds as FGFR inhibitors | 因塞特控股公司 | 2020-07-21 | — | — | CN | disclosed |
| CN-107383009-B | Substituted tricyclic compounds as FGFR inhibitors | 因塞特控股公司 | 2020-06-09 | — | — | CN | disclosed |
| US-20190127376-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS | INCYTE CORPORATION | 2019-05-02 | — | — | US | disclosed |
| US-20190127376-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS | INCYTE CORPORATION | 2019-05-02 | — | — | US | disclosed |
| US-20170137424-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS | INCYTE CORPORATION | 2017-05-18 | — | — | US | disclosed |
| US-20170137424-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS | INCYTE CORPORATION | 2017-05-18 | — | — | US | disclosed |
| US-9611267-B2 | Substituted tricyclic compounds as FGFR inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2017-04-04 | — | — | US | disclosed |
| US-9611267-B2 | Substituted tricyclic compounds as FGFR inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2017-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190127376-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS | FGFR3, FGFR1, FGFR2 | FGFR1 2/4885FGFR2 3/4885FGFR3 1/4885 |
| US-11840534-B2 | Substituted tricyclic compounds as FGFR inhibitors | FGFR3, FGFR1, FGFR2 | FGFR1 2/4885FGFR2 3/4885FGFR3 1/4885 |
| US-20200377504-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS | FGFR3, FGFR1, FGFR2 | FGFR1 2/4885FGFR2 3/4885FGFR3 1/4885 |
| US-20210380587-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS | FGFR3, FGFR1, FGFR2 | FGFR1 2/4885FGFR2 3/4885FGFR3 1/4885 |
| US-20170137424-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS | FGFR3, FGFR1, FGFR2 | FGFR1 2/4885FGFR2 3/4885FGFR3 1/4885 |
| US-11053246-B2 | Substituted tricyclic compounds as FGFR inhibitors | FGFR3, FGFR1, FGFR2 | FGFR1 2/4885FGFR2 3/4885FGFR3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.